Drug Trial Radar · NCT03980483
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Last checked: Nov 20, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,537
Actual
Start
May 16, 2019
Primary completion
Sep 15, 2021
Study completion Aug 16, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jun 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study \[contRAst 1 (201790: NCT03980483)\] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to MTX. The study will consist of a screening phase of up to 6 weeks followed by a 52-week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with MTX. Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165, may be included in the long-term extension study \[contRAst X (209564: NCT04333147)\]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.
Conditions
- Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab)Biological
GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Tofacitinib 5 mgDrug
Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
PlaceboDrug
Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
PlaceboDrug
Placebo cap (containing lactose) to be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With PlaceboTime frame: Week 12
Locations
76 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Bengbu, Anhui, China
GSK Investigational Site
Pingxiang, Jiangxi, China
GSK Investigational Site
Changchun, Jilin, China
GSK Investigational Site
Chengdu, Sichuan, China
GSK Investigational Site
Baja, Hungary
GSK Investigational Site
Balatonfüred, Hungary
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Kistarcsa, Hungary
GSK Investigational Site
Székesfehérvár, Hungary
GSK Investigational Site
Szentes, Hungary
GSK Investigational Site
Veszprém, Hungary
GSK Investigational Site
Ahmedabad, India
GSK Investigational Site
Ahmedabad, India
GSK Investigational Site
Ahmedabad, India
GSK Investigational Site
Ahmedabad, India
GSK Investigational Site
Banglore, India
GSK Investigational Site
Belagavi, India
GSK Investigational Site
Hubli, India
GSK Investigational Site
Hyderabad, India
GSK Investigational Site
Jaipur, India
GSK Investigational Site
Jaipur, India
GSK Investigational Site
Kolkata, India
GSK Investigational Site
Nagpur, India
GSK Investigational Site
Nagpur, India
GSK Investigational Site
Nashik, India
GSK Investigational Site
Nashik, India
GSK Investigational Site
New Delhi, India
GSK Investigational Site
Pimpri-Chinchwad, India
GSK Investigational Site
Pune, India
GSK Investigational Site
Pune, India
GSK Investigational Site
Rajkot, India
GSK Investigational Site
Surat, India
GSK Investigational Site
Vadodara, India
GSK Investigational Site
Verona, Veneto, Italy
GSK Investigational Site
Klang, Malaysia
GSK Investigational Site
Kuala Lumpur, Malaysia
GSK Investigational Site
Seremban, Negeri Sembilan, Malaysia
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.